| 注册
首页|期刊导航|武警医学|慢性胃病幽门螺杆菌初治及补救治疗疗效分析

慢性胃病幽门螺杆菌初治及补救治疗疗效分析

姚洪森 姚冬梅 张健 姚希贤 赵丽梅 刘艳

武警医学2012,Vol.23Issue(2):133-135,138,4.
武警医学2012,Vol.23Issue(2):133-135,138,4.

慢性胃病幽门螺杆菌初治及补救治疗疗效分析

Effect of Lizhuweisanlian combined with Killing Hp Capsules on 126 patients with chronic gastritis

姚洪森 1姚冬梅 2张健 1姚希贤 2赵丽梅 2刘艳3

作者信息

  • 1. 050051,石家庄,武警河北总队机关门诊部
  • 2. 050000石家庄,河北医科大学第二医院消化内科
  • 3. 050051,石家庄,武警河北总队卫生处
  • 折叠

摘要

Abstract

Objective To study the effect of lizhuweisanlian combined with Killing Hp capsules on patients with chronic gas-tropathy and the effect of remedy treatment with PPI triple therapy and Killing Hp capsules on refractory patients. Methods 139 patients under initial treatment were divided into two groups at random. The study group (A) was given lizhuweisanlian and Killing Hp capsules for seven days while the control group (B) was given lizhuweisanlian for seven days. 121 patients for retreatment were divided into treatment group ( group of supplement A, including Al, A2 and A3) and control group ( group of supplement B) . Group of supplement Al was given Lizhuweisanlian and Killing Hp capsules for 14 days, group of supplement A2 was given PPI triple sequential therapy plus Killing Hp capsules, and group of supplement A3 was given PPI triple therapy for 10 days. Results The eradication rate of helicobacter pylori in initial treatment group was 90. 60% in group A and 83. 33% in group B,P > 0. 05. The total incidence rate of adverse effects including nausea, poor appetite, abdominal discomfort and skin rash was lower in group A than in group B (2. 08% vs 10%) ,P>0.05. In remedy treatment patients, the eradication rate of helicobacter pylori was 63.33% in group Al and 60. 00% in group B,P>0.05. The effective rate in A2 and A3 was over 80% , group A2 (P<0.01) ,group A3 (P>0.05). As for such adverse effects as nausea, poor appetite and abdominal discomfort, there was significant difference between group A and group B(3.33% vs 20.00%) ,P<0.05. The total incidence rate of adverse effects was lower in group Al than in group B (6.67% vs 43.33%),P< 0.01. Conclusions Lizhuweisanlian, especially PPI triple therapeutic scheme combined with Killing Hp capsules, has good syner-gism and can increase the effect of killing Helicobacter pylori while reducing adverse effects.

关键词

丽珠维三联/灭Hp胶囊/幽门螺杆菌/补救治疗/序贯治疗

Key words

Lizhuweisanlian/ Killing Hp Capsules/ Helicobacter pylori/ remedy treatment/ triple therapy

分类

临床医学

引用本文复制引用

姚洪森,姚冬梅,张健,姚希贤,赵丽梅,刘艳..慢性胃病幽门螺杆菌初治及补救治疗疗效分析[J].武警医学,2012,23(2):133-135,138,4.

武警医学

OACSTPCD

1004-3594

访问量0
|
下载量0
段落导航相关论文